These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11744833)

  • 1. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
    Ribera E; Pou L; Lopez RM; Crespo M; Falco V; Ocaña I; Ruiz I; Pahissa A
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):450-3. PubMed ID: 11744833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.
    Ramachandran G; Hemanthkumar AK; Rajasekaran S; Padmapriyadarsini C; Narendran G; Sukumar B; Sathishnarayan S; Raja K; Kumaraswami V; Swaminathan S
    J Acquir Immune Defic Syndr; 2006 May; 42(1):36-41. PubMed ID: 16639340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
    Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
    Oudijk JM; McIlleron H; Mulenga V; Chintu C; Merry C; Walker AS; Cook A; Gibb DM; Burger DM
    AIDS; 2012 Jul; 26(12):1523-8. PubMed ID: 22546991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
    Matteelli A; Saleri N; Villani P; Bonkoungou V; Carvalho AC; Kouanda S; Sanou MJ; Simporé J; Monno L; Carosi G; Regazzi M; Dembele M
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):64-9. PubMed ID: 19731452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
    Prasitsuebsai W; Cressey TR; Capparelli E; Vanprapar N; Lapphra K; Chokephaibulkit K
    Pediatr Infect Dis J; 2012 Apr; 31(4):389-91. PubMed ID: 22146740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
    Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G
    J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
    Manosuthi W; Ruxrungtham K; Likanonsakul S; Prasithsirikul W; Inthong Y; Phoorisri T; Sungkanuparph S
    Clin Infect Dis; 2007 Jan; 44(1):141-4. PubMed ID: 17143831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.
    Lamorde M; Byakika-Kibwika P; Okaba-Kayom V; Ryan M; Coakley P; Boffito M; Namakula R; Kalemeera F; Colebunders R; Back D; Khoo S; Merry C
    J Antimicrob Chemother; 2011 Jan; 66(1):180-3. PubMed ID: 21047828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
    McIlleron H; Denti P; Cohn S; Mashabela F; Hoffmann JD; Shembe S; Msandiwa R; Wiesner L; Velaphi S; Lala SG; Chaisson RE; Martinson N; Dooley KE;
    J Antimicrob Chemother; 2017 Jul; 72(7):2028-2034. PubMed ID: 28419277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
    Manosuthi W; Sungkanuparph S; Thakkinstian A; Rattanasiri S; Chaovavanich A; Prasithsirikul W; Likanonsakul S; Ruxrungtham K
    Clin Infect Dis; 2006 Jul; 43(2):253-5. PubMed ID: 16779754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of indinavir on the pharmacokinetics of rifampicin in HIV-infected patients.
    Jaruratanasirikul S; Sriwiriyajan S
    J Pharm Pharmacol; 2001 Mar; 53(3):409-12. PubMed ID: 11291758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.
    Shah I; Swaminathan S; Ramachandran G; Kumar AK; Goray A; Chaddha U; Tayal S; Lala M
    Indian Pediatr; 2011 Dec; 48(12):943-7. PubMed ID: 21555806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.
    Matteelli A; Regazzi M; Villani P; De Iaco G; Cusato M; Carvalho AC; Caligaris S; Tomasoni L; Manfrin M; Capone S; Carosi G
    Curr HIV Res; 2007 May; 5(3):349-53. PubMed ID: 17504177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
    Autar RS; Wit FW; Sankote J; Mahanontharit A; Anekthananon T; Mootsikapun P; Sujaikaew K; Cooper DA; Lange JM; Phanuphak P; Ruxrungtham K; Burger DM
    Antivir Ther; 2005; 10(8):937-43. PubMed ID: 16430199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
    Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.